Nearly complete 1 hour 2-3 hours 8-12 hours 2-10 hours Hepatic 18.5-38% renal (unchanged) <1 ^/mL
Approved indications for propafenone include treatment of supraventricular arrhythmias and life-threatening ventricular arrhythmias in the absence of structural heart disease. Propafenone has been shown to increase mortality in patients with structural heart disease, and so extreme caution must be used in this subset of patients. As with flecainide, the patient should be hospitalized for initiation of therapy.
Was this article helpful?